Trials like CREST and Potomac show a consistent but modest event-free survival benefit when adding a PD-1 inhibitor to BCG for high-risk non-muscle-invasive bladder cancer. However, this comes with significant toxicity and no current overall survival benefit, creating a complex risk-benefit discussion for patients.

The Sac o six nineteen trial showed compelling results adding BCG to a chemo-immunotherapy backbone. However, the standard of care has already shifted to a newer combination (enfortumab vedotin and pembrolizumab), making it difficult to translate the study's findings into current practice and complicating the design of future trials.

Real-world data suggests that using one antibody-drug conjugate (ADC) immediately after another is often ineffective. A potential strategy to overcome this resistance is to administer a different class of chemotherapy before starting the second ADC.

The standard of care for non-muscle invasive bladder cancer, BCG, has been on backorder for nearly a decade. This creates a significant market opening for new treatments driven not just by clinical need for better efficacy, but by a fundamental failure in supply chain and access for the incumbent therapy.

While adding PD-1 inhibitors to standard BCG therapy in high-risk non-muscle-invasive bladder cancer improves event-free survival, it also introduces significant Grade 3 toxicity (around 24%) without mature overall survival data, making its risk-benefit profile questionable.

The CREST and Potomac trials showed adding immunotherapy to standard BCG treatment improves event-free survival by only ~5% at 24 months. This modest gain comes with a five-fold increase in significant adverse events, creating a crucial risk-reward discussion for patients.

By improving response rates before surgery, adding intravesical BCG can reduce the number of patients requiring follow-up adjuvant systemic therapy. This de-escalation strategy limits patients' overall exposure to toxic treatments and their side effects, a key benefit beyond improving primary outcomes.

In high-risk non-muscle invasive bladder cancer (NMIBC), trials like CREST and POTOMAC show adding a systemic immune checkpoint inhibitor to BCG therapy introduces significant toxicity. The benefit is primarily in local control, which may not justify the risk, especially with other effective intravesical options available.

Clinical trial data suggests immunotherapy's timing is crucial in early-stage TNBC. Given with chemotherapy before surgery (neoadjuvant), it improves outcomes. However, when given alone after surgery (adjuvant), the IMPASSION 030 trial showed no benefit and was halted for futility, indicating pre-surgical tumor priming is essential.